Inverness Medical Innovations signs on StatSure's HIV barrel test
This article was originally published in Clinica
Waltham, Massachusetts-based diagnostics company Inverness Medical Innovations (IMI) has signed a binding agreement with StatSure Diagnostic Systems to develop and market HIV tests based on the latter's barrel technology to the consumer and professional markets. Under the terms of the agreement, IMI will have exclusive worldwide rights to sell the tests in all consumer markets, and non-exclusive rights in professional markets. Framingham, Massachusetts-based StatSure will be responsible for the development and manufacture of the product, and will carry out the clinical trials - together with IMI - necessary for gaining regulatory approval.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.